Listed

Collegium Pharmaceutical, Inc: Form 10-Q for the period ended Sep 30, 2016

Filed with the SEC on Nov 10, 2016 and accepted by EDGAR at Nov 10, 2016, 16:02 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-07-01 to 2016-09-30$408.0kus-gaap:SalesRevenueGoodsNet
Revenue9 months2016-01-01 to 2016-09-30$408.0kus-gaap:SalesRevenueGoodsNet
Cost of revenue3 months2016-07-01 to 2016-09-30$29.0kus-gaap:CostOfGoodsSold
Cost of revenue9 months2016-01-01 to 2016-09-30$29.0kus-gaap:CostOfGoodsSold
Research and development3 months2016-07-01 to 2016-09-30$3.3mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2016-01-01 to 2016-09-30$11.6mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2016-07-01 to 2016-09-30$23.6mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2016-01-01 to 2016-09-30$55.3mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2016-07-01 to 2016-09-30−$26.4mus-gaap:OperatingIncomeLoss
Operating income9 months2016-01-01 to 2016-09-30−$66.5mus-gaap:OperatingIncomeLoss
Interest expense3 months2016-07-01 to 2016-09-30$2.0kus-gaap:InterestExpense
Interest expense9 months2016-01-01 to 2016-09-30$113.0kus-gaap:InterestExpense
Net income3 months2016-07-01 to 2016-09-30−$26.4mus-gaap:NetIncomeLoss
Net income9 months2016-01-01 to 2016-09-30−$66.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2016-07-01 to 2016-09-30−$1.13us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2016-01-01 to 2016-09-30−$2.85us-gaap:EarningsPerShareBasicAndDiluted
Basic EPS3 months2016-07-01 to 2016-09-30−$1.13us-gaap:EarningsPerShareBasic
Basic EPS9 months2016-01-01 to 2016-09-30−$2.85us-gaap:EarningsPerShareBasic
Capital expenditure9 months2016-01-01 to 2016-09-30$136.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-09-30$91.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-09-30$95.4mus-gaap:AssetsCurrent
Total assetsAt period end2016-09-30$98.7mus-gaap:Assets
Current liabilitiesAt period end2016-09-30$22.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-09-30$24.4mus-gaap:Liabilities
Shareholders' equityAt period end2016-09-30$74.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-16-009927. Last ingested by Listed: Nov 10, 2026, 23:07 ET. Listed shows no prices and gives no investment advice.